A. Ari Hakimi

In chronically stimulated human T cells, suppressed oxidative metabolism and nucleotide loss accompany MAP2K4 activation. Inhibiting MAP2K4 (with the MKK4/7 inhibitor BSJ-04-122) restored tumor-cell killing in vitro.

This study identifies developmental reversion to embryonic nephrogenesis in kidney cancer cells as a mechanism of resistance to immune checkpoint inhibitors.

This study identifies genomic and transcriptomic features on chromosome 1p associated with metachronous metastasis risk in ccRCC and develops a predictive model.

This study identifies SLC1A1/EAAT3 as an oncogenic transporter in ccRCC driven by H3K27ac, showing its role in sustaining metabolic programs and its potential as a therapeutic target.

This paper introduces a pooled sequencing strategy to address intratumoral genetic heterogeneity in cancer, showing it improves mutation detection and risk stratification while reducing costs.

The paper shows that mtDNA mutations in tumors are shaped by OXPHOS complexes, with specific mutational patterns in Complex I and V, and links these to improved survival in colorectal cancer.